Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

Research output: Contribution to journalJournal articlepeer-review

Standard

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes : what is up, what is down? / Nauck, M A; Vardarli, I; Deacon, C F; Holst, Jens Juul; Meier, Joachim.

In: Diabetologia, Vol. 54, No. 1, 2011, p. 10-18.

Research output: Contribution to journalJournal articlepeer-review

Harvard

Nauck, MA, Vardarli, I, Deacon, CF, Holst, JJ & Meier, J 2011, 'Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?', Diabetologia, vol. 54, no. 1, pp. 10-18. https://doi.org/10.1007/s00125-010-1896-4

APA

Nauck, M. A., Vardarli, I., Deacon, C. F., Holst, J. J., & Meier, J. (2011). Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia, 54(1), 10-18. https://doi.org/10.1007/s00125-010-1896-4

Vancouver

Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier J. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia. 2011;54(1):10-18. https://doi.org/10.1007/s00125-010-1896-4

Author

Nauck, M A ; Vardarli, I ; Deacon, C F ; Holst, Jens Juul ; Meier, Joachim. / Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes : what is up, what is down?. In: Diabetologia. 2011 ; Vol. 54, No. 1. pp. 10-18.

Bibtex

@article{f0c44af2ef904813b626274a337b313f,
title = "Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?",
abstract = "The incretin hormones gastric inhibitory polypeptide and especially glucagon-like peptide (GLP) have an important physiological function in augmenting postprandial insulin secretion. Since GLP-1 may play a role in the pathophysiology and treatment of type 2 diabetes, assessment of meal-related GLP-1 secretory responses in type 2 diabetic patients vs healthy individuals is of great interest. A common view states that GLP-1 secretion in patients with type 2 diabetes is deficient and that this applies to a lesser degree in individuals with impaired glucose tolerance. Such a deficiency is the rationale for replacing endogenous incretins with GLP-1 receptor agonists or re-normalising active GLP-1 concentrations with dipeptidyl peptidase-4 inhibitors. This review summarises the literature on this topic, including a meta-analysis of published studies on GLP-1 secretion in individuals with and without diabetes after oral glucose and mixed meals. Our analysis does not support the contention of a generalised defect in nutrient-related GLP-1 secretory responses in type 2 diabetes patients. Rather, factors are identified that may determine individual incretin secretory responses and explain some of the variations in published findings of group differences in GLP-1 responses to nutrient intake.",
keywords = "Animals, Diabetes Mellitus, Type 2, Glucagon-Like Peptide 1, Humans, Incretins, Meta-Analysis as Topic, Models, Biological",
author = "Nauck, {M A} and I Vardarli and Deacon, {C F} and Holst, {Jens Juul} and Joachim Meier",
year = "2011",
doi = "10.1007/s00125-010-1896-4",
language = "English",
volume = "54",
pages = "10--18",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer",
number = "1",

}

RIS

TY - JOUR

T1 - Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes

T2 - what is up, what is down?

AU - Nauck, M A

AU - Vardarli, I

AU - Deacon, C F

AU - Holst, Jens Juul

AU - Meier, Joachim

PY - 2011

Y1 - 2011

N2 - The incretin hormones gastric inhibitory polypeptide and especially glucagon-like peptide (GLP) have an important physiological function in augmenting postprandial insulin secretion. Since GLP-1 may play a role in the pathophysiology and treatment of type 2 diabetes, assessment of meal-related GLP-1 secretory responses in type 2 diabetic patients vs healthy individuals is of great interest. A common view states that GLP-1 secretion in patients with type 2 diabetes is deficient and that this applies to a lesser degree in individuals with impaired glucose tolerance. Such a deficiency is the rationale for replacing endogenous incretins with GLP-1 receptor agonists or re-normalising active GLP-1 concentrations with dipeptidyl peptidase-4 inhibitors. This review summarises the literature on this topic, including a meta-analysis of published studies on GLP-1 secretion in individuals with and without diabetes after oral glucose and mixed meals. Our analysis does not support the contention of a generalised defect in nutrient-related GLP-1 secretory responses in type 2 diabetes patients. Rather, factors are identified that may determine individual incretin secretory responses and explain some of the variations in published findings of group differences in GLP-1 responses to nutrient intake.

AB - The incretin hormones gastric inhibitory polypeptide and especially glucagon-like peptide (GLP) have an important physiological function in augmenting postprandial insulin secretion. Since GLP-1 may play a role in the pathophysiology and treatment of type 2 diabetes, assessment of meal-related GLP-1 secretory responses in type 2 diabetic patients vs healthy individuals is of great interest. A common view states that GLP-1 secretion in patients with type 2 diabetes is deficient and that this applies to a lesser degree in individuals with impaired glucose tolerance. Such a deficiency is the rationale for replacing endogenous incretins with GLP-1 receptor agonists or re-normalising active GLP-1 concentrations with dipeptidyl peptidase-4 inhibitors. This review summarises the literature on this topic, including a meta-analysis of published studies on GLP-1 secretion in individuals with and without diabetes after oral glucose and mixed meals. Our analysis does not support the contention of a generalised defect in nutrient-related GLP-1 secretory responses in type 2 diabetes patients. Rather, factors are identified that may determine individual incretin secretory responses and explain some of the variations in published findings of group differences in GLP-1 responses to nutrient intake.

KW - Animals

KW - Diabetes Mellitus, Type 2

KW - Glucagon-Like Peptide 1

KW - Humans

KW - Incretins

KW - Meta-Analysis as Topic

KW - Models, Biological

U2 - 10.1007/s00125-010-1896-4

DO - 10.1007/s00125-010-1896-4

M3 - Journal article

C2 - 20871975

VL - 54

SP - 10

EP - 18

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 1

ER -

ID: 38474765